MedX Health Corp, a teledermatology company, has announced the launch of its DermSecure skin screening services in Newfoundland and Labrador with the health authority Central Health.
MedX said the paid pilot program, which will span 60 days, will see the company implement its training program for nurses and supervisors to easily integrate the DermSecure Screening Platform into the Central Health patient service offerings.
Additionally, the company will provide training for dermatologists who will be reading the scans and establishing the protocols in conjunction with mobile services already provided by Newfoundland's health care system to improve access to dermatological services in remote communities across the province.
Upon the successful completion of the pilot, the MedX DermSecure Screening Platform will be made available to Central Health's patients across Newfoundland and Labrador.
READ: MedX Health closes first tranche of non-brokered private placement raising $250,000
"The paid pilot further verifies that our DermSecure platform meets all the necessary privacy and security requirements of a Canadian Provincial Government health care system," MedX director of North American sales, Paul Ziemer said in a statement.
"The challenges for physicians to effectively deliver care across this geography have been instrumental in Newfoundland and Labrador's prioritization and establishment of one of Canada's most robust telemedicine programs. The DermSecure platform and the images it provides for the doctors and dermatologists in the province will fit seamlessly into their telemedicine program and get the doctors and patients the information they need quickly and efficiently," he added.
Central Health is the second largest health authority in Newfoundland and Labrador, serving approximately 93,000 people, or 18% of the province's population, living in 176 communities from Charlottetown in the east, Fogo Island in the north, Harbour Breton in the south, to Baie Verte in the west. It provides a variety of primary, secondary, long-term care, community health, and other enhanced secondary services through regional referral centres, health centres, long-term care facilities and residential treatment centres.
MedX said implementing DermSecure will relieve the pressure facing family physicians and dermatologists in the Newfoundland and Labrador region, allowing them to alleviate the stress of melanoma screenings for their roster of patients in their practices quickly and efficiently.
In addition, it will speed up the management of non-life threatening but potentially difficult cases such as inflammatory conditions like acne, psoriasis and eczema.
"We are delighted to bring our DermSecure screening solution to the residents of Newfoundland and Labrador,” said MedX CEO Naman Demaghlatrous.
“MedX would like to thank Dr. Ian Landells, lead dermatologist for this pilot, the team at Central Health, and Ashley Dinn, Program Manager for the Virtual Care and Registry Integrity Unit at the Newfoundland and Labrador Centre for Health Information, for all of their hard work in driving this project to success," the CEO added.
Ontari-based MedX is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology.
SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds.
These products are cleared by Health Canada, the US Food and Drug Administration (FDA), the Therapeutic Goods Administration and Conformite Europeenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey.
Contact the author at jon.hopkins@proactiveinvestors.com